CN104066444A - 微粒疫苗制剂 - Google Patents

微粒疫苗制剂 Download PDF

Info

Publication number
CN104066444A
CN104066444A CN201280055234.5A CN201280055234A CN104066444A CN 104066444 A CN104066444 A CN 104066444A CN 201280055234 A CN201280055234 A CN 201280055234A CN 104066444 A CN104066444 A CN 104066444A
Authority
CN
China
Prior art keywords
antigen
seq
antigens
vaccine formulation
clauses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280055234.5A
Other languages
English (en)
Chinese (zh)
Inventor
F.贝杜-阿多
G.孔
E.雅各布森
C.默瑟
K.约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDS Biotechnology Corp
Original Assignee
PDS Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PDS Biotechnology Corp filed Critical PDS Biotechnology Corp
Priority to CN201910145079.XA priority Critical patent/CN110075292A/zh
Publication of CN104066444A publication Critical patent/CN104066444A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201280055234.5A 2011-09-12 2012-09-12 微粒疫苗制剂 Pending CN104066444A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910145079.XA CN110075292A (zh) 2011-09-12 2012-09-12 微粒疫苗制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161533512P 2011-09-12 2011-09-12
US61/533,512 2011-09-12
PCT/US2012/054786 WO2013039989A1 (en) 2011-09-12 2012-09-12 Particluate vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910145079.XA Division CN110075292A (zh) 2011-09-12 2012-09-12 微粒疫苗制剂

Publications (1)

Publication Number Publication Date
CN104066444A true CN104066444A (zh) 2014-09-24

Family

ID=47883670

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910145079.XA Pending CN110075292A (zh) 2011-09-12 2012-09-12 微粒疫苗制剂
CN201280055234.5A Pending CN104066444A (zh) 2011-09-12 2012-09-12 微粒疫苗制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910145079.XA Pending CN110075292A (zh) 2011-09-12 2012-09-12 微粒疫苗制剂

Country Status (8)

Country Link
US (2) US20150110823A1 (enExample)
EP (1) EP2755680B1 (enExample)
JP (2) JP6600459B2 (enExample)
CN (2) CN110075292A (enExample)
ES (1) ES2689799T3 (enExample)
PL (1) PL2755680T3 (enExample)
TW (1) TWI673062B (enExample)
WO (1) WO2013039989A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557035A (zh) * 2019-01-12 2021-10-26 卫理公会医院 自组装肽纳米颗粒和其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
BRPI0910464B1 (pt) 2008-04-17 2021-08-10 Pds Biotechnology Corporation Uso de uso de um lipídio catiônico quiral consistindo de r-dotap a preparação de composição farmacêutica
US20150110823A1 (en) * 2011-09-12 2015-04-23 Pds Biotechnology Corporation Particulate vaccine formulations
RU2649365C2 (ru) 2012-06-15 2018-04-02 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Вакцинные композиции с катионными липидами и способы применения
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
EP3374496A4 (en) 2015-11-13 2019-07-10 PDS Biotechnology Corporation LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
US20180221475A1 (en) * 2016-10-05 2018-08-09 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
SG11201902988UA (en) * 2016-10-05 2019-05-30 Pds Biotechnology Corp Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
US20220409708A1 (en) * 2019-11-01 2022-12-29 Korea Advanced Institute Of Science And Technology Small lipid nanoparticles, and cancer vaccine including same
WO2023145749A1 (ja) * 2022-01-27 2023-08-03 一般財団法人阪大微生物病研究会 免疫賦活剤
US20250281592A1 (en) 2022-04-22 2025-09-11 Universitat Autònoma De Barcelona Immunogenic composition with protein micro- and nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1909918A (zh) * 2004-02-20 2007-02-07 中国农业大学 T细胞免疫反应抑制剂
US20100221223A1 (en) * 2002-09-30 2010-09-02 Astellas Pharma Inc. Immune response induction method
CN102137675A (zh) * 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
JPH11510046A (ja) * 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
JP2004537501A (ja) * 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 肺への遺伝子送達のための安定化ポリマーエアロゾル
EP2481422A3 (en) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
WO2007022152A2 (en) * 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
EP1969001A2 (en) * 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007238559A (ja) * 2006-03-10 2007-09-20 Nagoya City Univ 未成熟樹状細胞活性化剤及びその使用
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2011109294A1 (en) * 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
US20150110823A1 (en) * 2011-09-12 2015-04-23 Pds Biotechnology Corporation Particulate vaccine formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221223A1 (en) * 2002-09-30 2010-09-02 Astellas Pharma Inc. Immune response induction method
CN1909918A (zh) * 2004-02-20 2007-02-07 中国农业大学 T细胞免疫反应抑制剂
CN102137675A (zh) * 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557035A (zh) * 2019-01-12 2021-10-26 卫理公会医院 自组装肽纳米颗粒和其用途
CN113557035B (zh) * 2019-01-12 2025-09-05 卫理公会医院 自组装肽纳米颗粒和其用途

Also Published As

Publication number Publication date
CN110075292A (zh) 2019-08-02
WO2013039989A1 (en) 2013-03-21
JP2014527965A (ja) 2014-10-23
US20150110823A1 (en) 2015-04-23
PL2755680T3 (pl) 2019-03-29
TW201317001A (zh) 2013-05-01
TWI673062B (zh) 2019-10-01
EP2755680A1 (en) 2014-07-23
EP2755680A4 (en) 2015-04-15
EP2755680B1 (en) 2018-07-04
JP6600459B2 (ja) 2019-10-30
JP2018065821A (ja) 2018-04-26
US20190275145A1 (en) 2019-09-12
ES2689799T3 (es) 2018-11-15

Similar Documents

Publication Publication Date Title
EP2755680B1 (en) Particulate vaccine formulations
US11911465B2 (en) Vaccine compositions and methods of use
US9486510B2 (en) Method to enhance an immune response of nucleic acid vaccination
TWI589298B (zh) 陽離子之脂質疫苗組合物及其使用方法
CN102137675A (zh) 通过阳离子脂质的对映体刺激免疫应答
HK40083470A (en) Vaccines comprising r-dotap

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140924